Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA

J. Y. PARK, Sangnae Cho, J. K. YOUN, D. I. KIM, R. V. CELLONA, T. T.FAJARDO Jr, G. P. WALSH, J. D. KIM

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Anti‐neural antibodies have been implicated to play a role in the pathogenesis of nerve damage in leprosy patients. To find the relationship between anti‐neural antibodies and clinical findings, we attempted to detect antibodies against neurofilament‐enriched proteins by ELISA in sera from leprosy patients. Of 289 sera from leprosy patients, 74(25–6%) had significant anti‐neural antibodies: in contrast, 1 (5–0%) of 20 tuberculosis patients and 11 (7–1%) of 154 controls were seroreactive to nerve antigen. When clinical types were considered, a significant level of anti‐neural IgG antibodies was detectable in 53 (30–1%) of 176 sera from lepromatous patients compared with 21(18–6%) of 113 sera from tuberculoid patients, indicating that lepromatous patients were more likely to be seropositive to nerve antigens in ELISA. Some of the ELISA‐reactive sera showed antibody reactivity with 38‐kD, 40‐kD and 43‐kD nerve antigens in Western blotting analysis. There was no apparent correlation between seroreactivity to nerve antigens and bacterial load in leprosy patients. Although there was no statistical significance, anti‐neural antibodies were detectable more often among the patients on chemotherapy than the untreated and among the patients with erythema nodosum leprosum than without. The results, therefore, suggest that anti‐neural antibodies arc elicited during the course of leprosy and may be associated with the extensiveness of nerve involvement in the patients.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalClinical & Experimental Immunology
Volume87
Issue number3
DOIs
Publication statusPublished - 1992 Jan 1

Fingerprint

Leprosy
Enzyme-Linked Immunosorbent Assay
Antigens
Antibodies
Serum
Erythema Nodosum
Bacterial Load
Tuberculosis
Immunoglobulin G
Western Blotting
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

PARK, J. Y. ; Cho, Sangnae ; YOUN, J. K. ; KIM, D. I. ; CELLONA, R. V. ; Jr, T. T.FAJARDO ; WALSH, G. P. ; KIM, J. D. / Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. In: Clinical & Experimental Immunology. 1992 ; Vol. 87, No. 3. pp. 368-372.
@article{5850bb48031b49e4ae46076416fb0126,
title = "Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA",
abstract = "Anti‐neural antibodies have been implicated to play a role in the pathogenesis of nerve damage in leprosy patients. To find the relationship between anti‐neural antibodies and clinical findings, we attempted to detect antibodies against neurofilament‐enriched proteins by ELISA in sera from leprosy patients. Of 289 sera from leprosy patients, 74(25–6{\%}) had significant anti‐neural antibodies: in contrast, 1 (5–0{\%}) of 20 tuberculosis patients and 11 (7–1{\%}) of 154 controls were seroreactive to nerve antigen. When clinical types were considered, a significant level of anti‐neural IgG antibodies was detectable in 53 (30–1{\%}) of 176 sera from lepromatous patients compared with 21(18–6{\%}) of 113 sera from tuberculoid patients, indicating that lepromatous patients were more likely to be seropositive to nerve antigens in ELISA. Some of the ELISA‐reactive sera showed antibody reactivity with 38‐kD, 40‐kD and 43‐kD nerve antigens in Western blotting analysis. There was no apparent correlation between seroreactivity to nerve antigens and bacterial load in leprosy patients. Although there was no statistical significance, anti‐neural antibodies were detectable more often among the patients on chemotherapy than the untreated and among the patients with erythema nodosum leprosum than without. The results, therefore, suggest that anti‐neural antibodies arc elicited during the course of leprosy and may be associated with the extensiveness of nerve involvement in the patients.",
author = "PARK, {J. Y.} and Sangnae Cho and YOUN, {J. K.} and KIM, {D. I.} and CELLONA, {R. V.} and Jr, {T. T.FAJARDO} and WALSH, {G. P.} and KIM, {J. D.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1111/j.1365-2249.1992.tb03004.x",
language = "English",
volume = "87",
pages = "368--372",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. / PARK, J. Y.; Cho, Sangnae; YOUN, J. K.; KIM, D. I.; CELLONA, R. V.; Jr, T. T.FAJARDO; WALSH, G. P.; KIM, J. D.

In: Clinical & Experimental Immunology, Vol. 87, No. 3, 01.01.1992, p. 368-372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA

AU - PARK, J. Y.

AU - Cho, Sangnae

AU - YOUN, J. K.

AU - KIM, D. I.

AU - CELLONA, R. V.

AU - Jr, T. T.FAJARDO

AU - WALSH, G. P.

AU - KIM, J. D.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Anti‐neural antibodies have been implicated to play a role in the pathogenesis of nerve damage in leprosy patients. To find the relationship between anti‐neural antibodies and clinical findings, we attempted to detect antibodies against neurofilament‐enriched proteins by ELISA in sera from leprosy patients. Of 289 sera from leprosy patients, 74(25–6%) had significant anti‐neural antibodies: in contrast, 1 (5–0%) of 20 tuberculosis patients and 11 (7–1%) of 154 controls were seroreactive to nerve antigen. When clinical types were considered, a significant level of anti‐neural IgG antibodies was detectable in 53 (30–1%) of 176 sera from lepromatous patients compared with 21(18–6%) of 113 sera from tuberculoid patients, indicating that lepromatous patients were more likely to be seropositive to nerve antigens in ELISA. Some of the ELISA‐reactive sera showed antibody reactivity with 38‐kD, 40‐kD and 43‐kD nerve antigens in Western blotting analysis. There was no apparent correlation between seroreactivity to nerve antigens and bacterial load in leprosy patients. Although there was no statistical significance, anti‐neural antibodies were detectable more often among the patients on chemotherapy than the untreated and among the patients with erythema nodosum leprosum than without. The results, therefore, suggest that anti‐neural antibodies arc elicited during the course of leprosy and may be associated with the extensiveness of nerve involvement in the patients.

AB - Anti‐neural antibodies have been implicated to play a role in the pathogenesis of nerve damage in leprosy patients. To find the relationship between anti‐neural antibodies and clinical findings, we attempted to detect antibodies against neurofilament‐enriched proteins by ELISA in sera from leprosy patients. Of 289 sera from leprosy patients, 74(25–6%) had significant anti‐neural antibodies: in contrast, 1 (5–0%) of 20 tuberculosis patients and 11 (7–1%) of 154 controls were seroreactive to nerve antigen. When clinical types were considered, a significant level of anti‐neural IgG antibodies was detectable in 53 (30–1%) of 176 sera from lepromatous patients compared with 21(18–6%) of 113 sera from tuberculoid patients, indicating that lepromatous patients were more likely to be seropositive to nerve antigens in ELISA. Some of the ELISA‐reactive sera showed antibody reactivity with 38‐kD, 40‐kD and 43‐kD nerve antigens in Western blotting analysis. There was no apparent correlation between seroreactivity to nerve antigens and bacterial load in leprosy patients. Although there was no statistical significance, anti‐neural antibodies were detectable more often among the patients on chemotherapy than the untreated and among the patients with erythema nodosum leprosum than without. The results, therefore, suggest that anti‐neural antibodies arc elicited during the course of leprosy and may be associated with the extensiveness of nerve involvement in the patients.

UR - http://www.scopus.com/inward/record.url?scp=0026555989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026555989&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.1992.tb03004.x

DO - 10.1111/j.1365-2249.1992.tb03004.x

M3 - Article

VL - 87

SP - 368

EP - 372

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -